Kaushal Mohit 4

What Happened
Director Kaushal Mohit reported two open‑market sales of Oncology Institute, Inc. (TOI) stock under a Rule 10b5‑1 plan. He sold 57,286 shares on April 14, 2026 for roughly $200,598 (reported @ $3.50) and 38,433 shares on April 16, 2026 for roughly $134,535 (reported @ $3.50), totaling 95,719 shares and approximately $335,133 in proceeds. Sales are routine dispositions rather than purchases (not a bullish insider buy).

Key Details

• Transaction dates and reported prices:
  • Apr 14, 2026 — 57,286 shares disposed, reported price $3.50 (footnote: VWAP $3.5017; actual trade prices ranged $3.50–$3.53).
  • Apr 16, 2026 — 38,433 shares disposed, reported price $3.50 (footnote: VWAP $3.5005; actual trade prices ranged $3.50–$3.505).
• Total shares sold: 95,719; total proceeds ≈ $335,133.
• Sales were made pursuant to a Rule 10b5‑1 trading plan adopted by Mr. Mohit on December 16, 2025 (pre‑arranged plan).
• The filer offered to provide detailed per‑price sale counts to the SEC upon request (per footnotes).
• Filing: Report filed Apr 16, 2026 covering sales on Apr 14 and Apr 16; appears to have been submitted within the required Form 4 timing windows (not marked late).

Context
A 10b5‑1 plan indicates these were pre‑scheduled sales, which are generally viewed as routine rather than signals of new insider sentiment. For retail investors, purchases by insiders tend to be more informative; sales can reflect diversification, tax planning, or other personal reasons rather than a view on company fundamentals.